Accretion Pharmaceuticals IPO Upcoming
Already have an account? Apply now
Schedule of Accretion Pharmaceuticals
| Issue open date | 14 May 2025 |
| Issue close date | 16 May 2025 |
| UPI mandate deadline | 16 May 2025 (5 PM) |
| Allotment finalization | 19 May 2025 |
| Refund initiation | 20 May 2025 |
| Share credit | 20 May 2025 |
| Listing date | 21 May 2025 |
| Mandate end date | 31 May 2025 |
| Lock-in end date for anchor investors (50%) | 18 Jun 2025 |
| Lock-in end date for anchor investors (remaining) | 17 Aug 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Accretion Pharmaceuticals
Accretion Pharmaceuticals began as a partnership firm in 2012, founded by four promoters with a vision to provide high-quality, affordable healthcare products. It started manufacturing in 2014 in Ahmedabad, Gujarat, and was converted into a public limited company in November 2053. The company produces a wide range of pharmaceutical products including tablets, capsules, oral liquids, ointments, and powders. It also engages in loan license and contract manufacturing for various marketers. Accretion is ISO certified and led by an experienced board and management team.
Financials of Accretion Pharmaceuticals
*All figures are in ₹ Crores.
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹29.75 crores |
| Fresh Issue | ₹29.75 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Capital expenditure towards purchase of new equipment/ machineries, etc |
2.69 (9.04%) |
| Capital expenditure towards upgradation of existing manufacturing facility | 4.65 (15.63%) |
| Repayment/prepayment of certain borrowings availed by the Company | 1.60 (5.38%) |
Strengths
- Certified with ISO 9001:2015, 14001:2015, and 22000:2018 for quality and safety standards
- Operates both in-house manufacturing and contract/loan licensing for corporate clients
- Broad product range including tablets, capsules, syrups, ointments, and medicated cosmetics
- Strong financial growth with PAT up from ₹10.39 lakhs in FY23 to ₹387.53 lakhs in FY24
- Promoters and management have significant experience in pharmaceutical operations
Risks
- Ongoing legal case related to child labor law violations could impact reputation
- Exposure to interest rate risk on borrowings may affect financial stability
- Promoter group entities operate in a similar line of business, creating potential conflicts of interest
- Business heavily reliant on contract manufacturing, which may face demand variability
- No history of dividend payments may be a concern for income-seeking investors
Allotment Status for Accretion Pharmaceuticals
To check your allotment status – click here.